1α,25-dihydroxyvitamin D3 and resolvin D1 retune the balance between amyloid-β phagocytosis and inflammation in Alzheimer's disease patients

Journal of Alzheimer's Disease

Volumn 34, Issue 1, 2013, Pages 155-170

  Mizwicki, Mathew T ^a   Liu, Guanghao ^a   Fiala, Milan ^a   Magpantay, Larry ^a   Sayre, James ^b   Siani, Avi ^a   Mahanian, Michelle ^a   Weitzman, Rachel ^a   Hayden, Eric Y ^a   Rosenthal, Mark J ^a   Nemere, Ilka ^c   Ringman, John ^a   Teplow, David B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UTAH STATE UNIVERSITY   (United States)

Author keywords

1 ,25 dihydroxyvitamin D3; Alzheimer's disease; amyloid ; phagocytosis; resolvin D1

Indexed keywords

AMYLOID BETA PROTEIN; CALCITRIOL; CALCIUM; CCL1 CHEMOKINE; CXCL1 CHEMOKINE; CYCLIC AMP DEPENDENT PROTEIN KINASE; DOCOSAHEXAENOIC ACID; FATTY ACID DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PEPTIDES AND PROTEINS; PERTUSSIS TOXIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN DISULFIDE ISOMERASE A3 RECEPTOR; PROTEIN ITGB2; RECEPTOR; RESOLVIN D1; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATION; MACROPHAGE; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHAGOCYTOSIS; PRIORITY JOURNAL;

EID: 84874304462     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-121735     Document Type: Article

References (44)

1. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297, 353-356. (Pubitemid 34790756)
2. Wyss-Coray T, Rogers J (2012) Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med 2, a006346.
3. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ (2010) Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Scienc 330, 1774.
4. Sagare AP, Bell RD, Zlokovic BV (2012) Neurovascular defects and faulty amyloid-beta vascular clearance in Alzheimer's disease. J Alzheimers Dis, doi: 10.3233/JAD-2012-129037 Epub ahead of print].
5. Tanzi RE, Moir RD, Wagner SL (2004) Clearance of Alzheimer's Abeta peptide: The many roads to perdition. Neuron 43, 605-608. (Pubitemid 39179722)
6. Miners JS, Baig S, Palmer J, Palmer LE, Kehoe PG, Love S (2008) Abeta-degrading enzymes in Alzheimer's disease. Brain Pathol 18, 240-252.
7. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T (2000) Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6, 916-919. (Pubitemid 30644751)
8. Selkoe DJ (2011) Resolving controversies on the path to Alzheimer's therapeutics. Nat Med 17, 1060-1065.
9. Patton RL, Kalback WM, Esh CL, Kokjohn TA, Van Vickle GD, Luehrs DC, Kuo YM, Lopez J, Brune D, Ferrer I, Masliah E, Newel AJ, Beach TG, Castano EM, Roher AE (2006) Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: A biochemical analysis. Am J Pathol 169, 1048-1063. (Pubitemid 44411966)
10. Schnabel J (2011) Vaccines: Chasing the dream. Nature 475, S18-S19.
11. Fiala M, Liu PT, Espinosa-Jeffrey A, Rosenthal MJ, Bernard G, Ringman JM, Sayre J, Zhang L, Zaghi J, Dejbakhsh S, Chiang B, Hui J, Mahanian M, Baghaee A, Hong P, Cashman J (2007) Innate immunity and transcription of MGAT-III and Toll-like receptors in Alzheimer's disease patients are improved by bisdemethoxycurcumin. Proc Natl Acad Sci U S A 104, 12849-12854. (Pubitemid 47255243)
12. Avagyan H, Goldenson B, Tse E, Masoumi A, Porter V, Wiedau-Pazos M, Sayre J, Ong R, Mahanian M, Koo P, Bae S, Micic M, Liu PT, Rosenthal MJ, Fiala M (2009) Immune blood biomarkers of Alzheimer disease patients. J Neuroimmunol 210, 67-72.
13. Zaghi J, Goldenson B, Inayathullah M, Lossinsky AS, Masoumi A, Avagyan H, Mahanian M, Bernas M, Weinand M, Rosenthal MJ, Espinosa-Jeffrey A, de Vellis J, Teplow DB, Fiala M (2009) Alzheimer disease macrophages shuttle amyloid-beta from neurons to vessels, contributing to amyloid angiopathy. Acta Neuropathol 117, 111-124.
14. Masoumi A, Goldenson B, Ghirmai S, Avagyan H, Zaghi J, Abel K, Zheng X, Espinosa-Jeffrey A, Mahanian M, Liu PT, Hewison M, Mizwicki M, Cashman J, Fiala M (2009) 1alpha, 25-dihydroxyvitamin D3 interacts with curcuminoids to stimulate amyloid-beta clearance by macrophages of Alzheimer's disease patients. J Alzheimers Dis 17, 703-717.
15. Serhan CN, Hong S, Gronert K, Colgan SP, Devchand PR, Mirick G, Moussignac RL (2002) Resolvins: A family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med 196, 1025-1037. (Pubitemid 35231761)
16. Bazan NG, MolinaMF, GordonWC (2011) Docosahexaenoic Acid signalolipidomics in nutrition: Significance in aging, neuroinflammation, macular degeneration, Alzheimer's, and other neurodegenerative diseases. Annu Rev Nutr 31, 321-351.
17. Menegaz D, Mizwicki MT, Barrientos-Duran A, Chen N, Henry HL, Norman AW (2011) Vitamin D receptor (VDR) regulation of voltage-gated chloride channels by ligands preferring a VDR-alternative pocket (VDR-AP). Mol Endocrinol 25, 1289-1300.
18. Mizwicki MT, Norman AW (2009) The vitamin D sterolvitamin D receptor ensemble model offers unique insights into both genomic and rapid-response signaling. Sci Signal 2, re4.
19. Dursun E, Gezen-Ak D, Yilmazer S (2011) A novel perspective for Alzheimer's disease: Vitamin D receptor suppression by amyloid-beta and preventing the amyloid-beta induced alterations by vitamin D in cortical neurons. J Alzheimers Dis 23, 207-219.
20. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, StreitW, Strohmeyer R, Tooyoma I, VanMuiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T (2000) Inflammation and Alzheimer's disease. Neurobiol Aging 21, 383-421. (Pubitemid 30349107)
21. McCoyMK, Martinez TN, Ruhn KA, Szymkowski DE, Smith CG, Botterman BR, Tansey KE, TanseyMG (2006) Blocking soluble tumor necrosis factor signaling with dominantnegative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease. J Neurosci 26, 9365-9375. (Pubitemid 44396849)
22. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S (2011) The pro-and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta 1813, 878-888.
23. Shaftel SS, Griffin WS, O'Banion MK (2008) The role of interleukin-1 in neuroinflammation and Alzheimer disease: An evolving perspective. J Neuroinflammation 5, 7.
24. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944. (Pubitemid 14076461)
25. Sequeira VB, Rybchyn MS, Tongkao-On W, Gordon-Thomson C, Malloy PJ, Nemere I, Norman AW, Reeve VE, Halliday GM, Feldman D, Mason RS (2012) The role of the vitamin D receptor and ERp57 in photoprotection by 1alpha, 25-dDihydroxyvitamin D3. Mol Endocrinol 26, 574-582.
26. Maji SK, Ogorzalek Loo RR, Inayathullah M, Spring SM, Vollers SS, Condron MM, Bitan G, Loo JA, Teplow DB (2009) Amino acid position-specific contributions to amyloid betaprotein oligomerization. J Biol Chem 284, 23580-23591.
27. Walsh DM, Hartley DM, Kusumoto Y, Fezoui Y, Condron MM, Lomakin A, Benedek GB, Selkoe DJ, TeplowDB (1999) Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J Biol Chem 274, 25945-25952.
28. Krishnamoorthy S, Recchiuti A, Chiang N, Yacoubian S, Lee CH, Yang R, Petasis NA, Serhan CN (2010) Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc Natl Acad Sci U S A 107, 1660-1665.
29. Mizwicki MT, Menegaz D, Zhang J, Barrientos-Duran A, Tse S, Cashman JR, Griffin PR, Fiala M (2012) Genomic and nongenomic signaling induced by 1alpha, 25 (OH)2-vitamin D3 promotes the recovery of amyloid-beta phagocytosis by Alzheimer's disease macrophages. J Alzheimers Dis 29, 51-62.
30. Journiac N, Jolly S, Jarvis C, Gautheron V, Rogard M, Trembleau A, Blondeau JP, Mariani J, Vernet-der Garabedian B (2009) The nuclear receptor ROR (alpha) exerts a bi-directional regulation of IL-6 in resting and reactive astrocytes. Proc Natl Acad Sci U S A 106, 21365-21370.
31. MizwickiMT, Bula CM, Bishop JE, NormanAW (2007) New insights into Vitamin D sterol-VDR proteolysis, allostery, structure-function from the perspective of a conformational ensemble model. J Steroid Biochem Mol Biol 103, 243-262. (Pubitemid 46401298)
32. MizwickiMT, Menegaz D, Zhang J, Barrientos-Duran A, Tse S, Cashman JR, Griffin PR, Fiala M (2012) Genomic and nongenomic signaling induced by 1alpha, 25 (OH)2-vitamin D3 Promotes the recovery of amyloid-beta phagocytosis by Alzheimer's disease macrophages. J Alzheimers Dis 29, 51-62.
33. Eckert A, Steiner B, Marques C, Leutz S, Romig H, Haass C, Muller WE (2001) Elevated vulnerability to oxidative stressinduced cell death and activation of caspase-3 by the Swedish amyloid precursor protein mutation. J Neurosci Res 64, 183-192.
34. Roychaudhuri R, Yang M, Hoshi MM, Teplow DB (2009) Amyloid beta-protein assembly and Alzheimer disease. J Biol Chem 284, 4749-4753.
35. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling RA, Salloway S, Morris JC, the Dominantly Inherited Alzheimer N (2012) Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 367, 795-804.
36. Fiala M, Mahanian M, Rosenthal M, Mizwicki MT, Tse E, Cho T, Sayre J, Weitzman R, PorterV (2011)MGAT3mRNA: Abiomarker for prognosis and therapy of Alzheimer's disease by vitamin D and curcuminoids. J Alzheimers Dis 25, 135-144.
37. Landreth GE, Reed-Geaghan EG (2009) Toll-like receptors in Alzheimer's disease. Curr Top Microbiol Immunol 336, 137-153.
38. Liu L, Aboud O, Jones RA, Mrak RE, Griffin ST, Barger SW (2011) Apolipoprotein E expression is elevated by interleukin and other interleukin 1-induced factors. J Neuroinflammation 8, 175.
39. Kitazawa M, Cheng D, Tsukamoto MR, Koike MA, Wes PD, Vasilevko V, Cribbs DH, LaFerla FM (2011) Blocking IL-1 signaling rescues cognition, attenuates tau pathology, and restores neuronal beta-catenin pathway function in an Alzheimer's disease model. J Immunol 187, 6539-6549.
40. Smith AJ, Keen LJ, Billingham MJ, Perry MJ, Elson CJ, Kirwan JR, Sims JE, Doherty M, Spector TD, Bidwell JL (2004) Extended haplotypes and linkage disequilibrium in the IL1R1-IL1A-IL1B-IL1RN gene cluster: Association with knee osteoarthritis. Genes Immun 5, 451-460. (Pubitemid 39263881)
41. Holick MF (2008) Vitamin D: A D-Lightful health perspective. Nutr Rev 66, S182-S194.
42. Fernandes de Abreu DA, Eyles D, Feron F (2009) Vitamin D, a neuro-immunomodulator: Implications for neurodegenerative and autoimmune diseases. Psychoneuroendocrinology 34 (Suppl 1), S265-S277.
43. Zhao Y, Calon F, Julien C, Winkler JW, Petasis NA, Lukiw WJ, Bazan NG (2011) Docosahexaenoic acid-derived neuroprotectin D1 induces neuronal survival via secretase-and PPARgamma-mediated mechanisms in Alzheimer's disease models. PLoS One 6, e15816.
44. Dickens AP, Lang IA, Langa KM, Kos K, Llewellyn DJ (2011) Vitamin D, cognitive dysfunction and dementia in older adults. CNS Drugs 25, 629-639.